AstraZeneca Reports Q3 2025 Results: China Revenue Reaches $5.28B, Enhertu Global Sales Surpass $3.57B

Nov 06, 2025 15:28 CST Updated 15:28

AstraZeneca

Biopharmaceutical Manufacturer

On November 6, AstraZeneca announcedQ3 2025 Earnings Report,Total revenue in the third quarter was $15.191 billion, a year-on-year increase of 10%.(Calculated at constant exchange rates CER, same below). Total revenue for the first nine months was $43.236 billion, representing an 11% increase year-over-year, with product revenue$431.43 billion（+11%），R&D investment of $10.37 billion, an increase of 16% over the same period last year.

Screenshot source: AstraZeneca earnings report, same as below (The complete PPT can be downloaded at the end of the article.）

From a regional perspective, the United States remains AstraZeneca's primary market, with revenue in the first three quarters of 2025 reaching $18.517 billion, an increase of 11%; revenue in Europe was $9.16 billion, up 9%; revenue in emerging markets was $11.657 billion, growing by 13%, of whichRevenue in China reached $5.279 billion, growing by 5%,Revenue from China accounts for 12% of AstraZeneca's total revenue.。

From the product perspective,Farxiga(Dapagliflozin)In$6.345 billion (+11%)continues to secure the top spot as AstraZeneca's best-selling drug. Tagrisso(Osimertinib)and Imfinzi(Durvalumab)Have respectively wonUSD 5.352 billion (+10%)、$4.317 billion (+25%), ranking second and third.

From the perspective of disease areas,Total Revenue from Oncology OperationsIncreased by 16% to USD 18.59 billion. Among themTagrisso(Osimertinib)Revenue of $5.352 billion (+10%),Imfinzi(Durvalumab)Revenue of $4.317 billion (+25%)、BTK InhibitorCalquence(Acalabrutinib)Revenue of $2.551 billion (+10%)、PARP InhibitorLynparza(Olaparib)Revenue of $2.401 billion (+7%),CTLA4 Antibody Imjudo(Tremelimumab)Revenue of $253 million (+21%),World's First AKT Inhibitor Truqap(Capisetron)Sales in the first three quarters were$4.95 billion (+85%).

Among them, the heavyweight ADC product Enhertu co-developed by Daiichi Sankyo and AstraZeneca(Trastuzumab Deruxtecan)Total sales for the first nine months were $3.575 billion, compared to the same period in 2024.($2.729 billion)Increased by 31%; co-launchedTROP2 ADC Datroway(Derda Botu Monoclonal Antibody)Have successively entered the Japanese, American, and European markets, contributing to AstraZeneca's performance in the first three quarters.$0.38 billion。

Rare Disease BusinessRevenue of $6.752 billion, up 6%. Specifically, Ultomiris(Relatlimab)Revenue$3.453 billion (+21%), Complement C5 Inhibitor Soliris(Eculizumab)Revenue of $1.436 billion (-28%), Strensiq(Asfotase Alfa)Revenue of $1.188 billion (+19%).

CVRM(Cardiovascular, Renal and Metabolic Diseases)Performance in the field is equally outstanding,Total revenue increased by 5% to reach 9.728 billion USD. Among them, Farxiga(Dapagliflozin)Achieved$63.45 billionIncome（+11%），Lokelma(Sodium Zirconium Cyclosilicate)And Wainua（eplontersen）Both new products have achieved good growth. In addition,Highly Selective Aldosterone Synthase InhibitorBaxdrostat Phase IIIThe BaxHTN clinical trial has been successful and is expected to be submitted for marketing approval within the year.Expected to become another blockbuster product in AstraZeneca's CVRM field.

R&I(Respiratory and Immunology)Field Revenue$64.93 billion, increased by 13%. Among them, Breztri(Glycopyrronium Bromide + Formoterol + Budesonide)Revenue of $906 million (+26%),Fasenra (Benrilizumab)Revenue of $1.451 billion (+19%),Tezspire(Tezelimab)Revenue of $770 million (+63%).

In addition, the financial report shows that AstraZeneca has terminated one Phase III, two Phase II, and two other Phase II studies.